白細胞介素33及其受體ST2在肺部疾病中的作用研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

郭微微 ,  王麗慧 , 楊炯

武漢大學中南醫院呼吸內科(湖北武漢 430071);

Corresponding?author：

王麗慧, Email: 1004611723@qq.com

Keywords：

DOI：

10.7507/1671-6205.2015146

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 郭微微, 王麗慧, 楊炯. 白細胞介素33及其受體ST2在肺部疾病中的作用研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(6): 604-610. doi: 10.7507/1671-6205.2015146 Copy

1.	?Sims JE, Nicklin MJH, Bazan JF. A new nomenclature for IL-1-family genes. Immunology,2001,22:536-537.
2.	Schmitz J, Owyang A, Oldham E. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity,2005,23:479-490.
3.	Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33:the new kid in the IL-1 family. Nat Rev Immunol,2010,10:103-110.
4.	Baekkevold ES, Roussigne M, Yamanaka T. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol,2003,163:69-79.
5.	Werman A, Werman-Venkert R, White R. The precursor form of IL-1 is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA,2004,101:2434-2439.
6.	Carriere V, Roussel L, Ortega N. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA,2007,104:282-287.
7.	Werenskiold AK, Hoffmann S, Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol,1989,9:5207-5214.
8.	Superti-Furga G, Bergers G, Picard D, et al. Hormone-dependent transcriptional regulation and cellular transformation by Fos-steroid receptor fusion proteins. Biochemistry,1991,88:5114-5118.
9.	Lanahan A, Williams JB, Sanders LK, et al. Growth factor-induced delayed early response genes. Mol Cell Biol,1992,12:3919-3929.
10.	Yanagisawa K, Takagi T, Tsukamoto T, et al. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett,1993,318:83-87.
11.	Li HJ, Tago K, Io K, et al. The cloning and nucleotide sequence of human ST2L cDNA. Genomics,2000,67:284-290.
12.	Tominaga S, Kuroiwa K, Tago K, et al. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun,1999,264:14-18.
13.	McMahan CJ, Slack JL, Mosley B, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J,1991,10:2821-2832.
14.	Shao D, Perros F, Caramori G, et al. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochem Biophys Res Commun,2014,451:8-14.
15.	Kumar S, Minnich MD, Young PR. ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1. J Biol Chem,1995,270:27905-27913.
16.	Yanagisawa K, Naito Y, Kuroiwa K, et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem,1997,121:95-103.
17.	Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo:a novel;'alarmin'? PloS One,2008,3:e3331.
18.	Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest,2007,117:1538-1549.
19.	Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine,2012,60:514-521.
20.	Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA,2009,106:9021-9026.
21.	Luthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity,2009,31:84-98.
22.	Talabot-Ayer D, Lamacchia C, Gabay C, et al. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem,2009,284:19420-19426.
23.	Lamkanfi M, Kanneganti TD, Van Damme P, et al. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics,2008,7:2350-2363.
24.	Hayakawa M, Hayakawa H, Matsuyama Y, et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun,2009,387:218-222.
25.	Lingel A, Weiss TM, Niebuhr M, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure,2009,17:1398-1410.
26.	Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine,2008,42:358-364.
27.	Pushparaj PN, Tay HK, H'ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA,2009,106:9773-9778.
28.	Funakoshi-Tago M, Tago K, Hayakawa M, et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal,2008,20:1679-1686.
29.	Allakhverdi Z, Smith DE, Comeau MR, et al. Cutting Edge:The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol,2007,179:2051-2054.
30.	Moulin D, Donzé O, Talabot-Ayer D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine,2007,40:216-225.
31.	Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 Induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol,2008,181:4780-4790.
32.	Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev,2008,223:20-38.
33.	Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol,2007,37:2779-2786.
34.	Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA,1998,95:6930-6935.
35.	Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med,1999,190:895-902.
36.	Nakae S, Iwakura Y, Suto H, et al. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol,2007,81:1258-1268.
37.	Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med,1998,187:787-794.
38.	Hoshino K, Kashiwamura S, Kuribayashi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med,1999,190:1541-1547.
39.	Townsend MJ, Fallon PG, Matthews DJ, et al. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med,2000,191:1069-1075.
40.	Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation,2002,106:2961-2966.
41.	Smithgall MD, Comeau MR, Yoon BR, et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol,2008,20:1019-1030.
42.	Chen CC, Grimbaldeston MA, Tsai M, et al. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci USA,2005,102:11408-11413.
43.	Likura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest,2007,87:971-978.
44.	Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol,2007,82:1481-1490.
45.	Suzukawa M, Likura M, Koketsu R, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol,2008,181:5981-5989.
46.	Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol,2008,20:791-800.
47.	Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood,2009,113:1526-1534.
48.	Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol,2009,86:769-778.
49.	Cherry WB, Yoon J, Bartemes KR, et al. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol,2008,121:1484-1490.
50.	Suzukawa M, Koketsu R, Likura M, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest,2008,88:1245-1253.
51.	Miller AM, Liew FY. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. Pharmacol Ther,2011,131:179-186.
52.	Aoki S, Hayakawa M, Ozaki H. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem,2010,335:75-81.
53.	Ciccone MM, Cortese F, Gesualdo M, et al. A novel cardiac bio-marker:ST2:a review. Molecules,2013,18:15314-15328.
54.	Carlomagno G, Messalli G, Melillo RM, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol,2013,168:1545-1547.
55.	Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol,2010,185:5743-5750.
56.	Oshikawa K, Yanagisawa K, Tominaga S, et al. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun,2002,299:18-24.
57.	Trajkovic V, Sweet MJ, Xu D. T1/ST2--an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev,2004,15:87-95.
58.	Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med,2004,30:1468-1473.
59.	Martinez-Rumayor A, Camargo CA, Green SM, et al. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol,2008,130:578-584.
60.	Kearley J, Buckland KF, Mathie SA, et al. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med,2009,179:772-781.
61.	Prefontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma:evidence of expression by airway smooth muscle cells. J Immunol,2009,183:5094-5103.
62.	Kurowska-Stolarska M, Stolarski B, Kewin P, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol,2009,183:6469-6477.
63.	Oshikawa K, KUroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med,2001,164:277-281.
64.	Liu X, Li M, Wu Y, et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun,2009,386:181-185.
65.	Mangan NE, Dasvarma A, McKenzie AN. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol,2007,37:1302-1312.
66.	Hayashi H, Kawakita A, Okazaki S, et al. IL-33 enhanced the proliferation and constitutive production of IL-13 and IL-5 by fibrocytes. Biomed Res Int,2014,2014:738625.
67.	Xia J, Zhao J, Shang J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol,2015,308:L619-L627.
68.	Qiu C, Li Y, Li M, et al. Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice. Immunology,2013,138:76-82.
69.	Walzl G, Matthews S, Kendall S, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. Exp Med,2001,193:785-792.
70.	Tang Y, Guan Y, Liu Y, et al. The role of the serum IL-33/sST2 axis and inflammatory cytokines in chronic obstructive pulmonary disease. J Interferon Cytokine Res,2014,34:162-168.
71.	Martin TR, Mathison JC, Tobias PS, et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest,1992,90:2209-2219.
72.	Zhao L, Yao L, Yuan L, et al. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome. Cytokine,2013,64:22-24.

1. ?Sims JE, Nicklin MJH, Bazan JF. A new nomenclature for IL-1-family genes. Immunology,2001,22:536-537.
2. Schmitz J, Owyang A, Oldham E. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity,2005,23:479-490.
3. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33:the new kid in the IL-1 family. Nat Rev Immunol,2010,10:103-110.
4. Baekkevold ES, Roussigne M, Yamanaka T. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol,2003,163:69-79.
5. Werman A, Werman-Venkert R, White R. The precursor form of IL-1 is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA,2004,101:2434-2439.
6. Carriere V, Roussel L, Ortega N. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA,2007,104:282-287.
7. Werenskiold AK, Hoffmann S, Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol,1989,9:5207-5214.
8. Superti-Furga G, Bergers G, Picard D, et al. Hormone-dependent transcriptional regulation and cellular transformation by Fos-steroid receptor fusion proteins. Biochemistry,1991,88:5114-5118.
9. Lanahan A, Williams JB, Sanders LK, et al. Growth factor-induced delayed early response genes. Mol Cell Biol,1992,12:3919-3929.
10. Yanagisawa K, Takagi T, Tsukamoto T, et al. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett,1993,318:83-87.
11. Li HJ, Tago K, Io K, et al. The cloning and nucleotide sequence of human ST2L cDNA. Genomics,2000,67:284-290.
12. Tominaga S, Kuroiwa K, Tago K, et al. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun,1999,264:14-18.
13. McMahan CJ, Slack JL, Mosley B, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J,1991,10:2821-2832.
14. Shao D, Perros F, Caramori G, et al. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochem Biophys Res Commun,2014,451:8-14.
15. Kumar S, Minnich MD, Young PR. ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1. J Biol Chem,1995,270:27905-27913.
16. Yanagisawa K, Naito Y, Kuroiwa K, et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem,1997,121:95-103.
17. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo:a novel;'alarmin'? PloS One,2008,3:e3331.
18. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest,2007,117:1538-1549.
19. Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine,2012,60:514-521.
20. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA,2009,106:9021-9026.
21. Luthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity,2009,31:84-98.
22. Talabot-Ayer D, Lamacchia C, Gabay C, et al. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem,2009,284:19420-19426.
23. Lamkanfi M, Kanneganti TD, Van Damme P, et al. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics,2008,7:2350-2363.
24. Hayakawa M, Hayakawa H, Matsuyama Y, et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun,2009,387:218-222.
25. Lingel A, Weiss TM, Niebuhr M, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure,2009,17:1398-1410.
26. Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine,2008,42:358-364.
27. Pushparaj PN, Tay HK, H'ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA,2009,106:9773-9778.
28. Funakoshi-Tago M, Tago K, Hayakawa M, et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal,2008,20:1679-1686.
29. Allakhverdi Z, Smith DE, Comeau MR, et al. Cutting Edge:The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol,2007,179:2051-2054.
30. Moulin D, Donzé O, Talabot-Ayer D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine,2007,40:216-225.
31. Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 Induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol,2008,181:4780-4790.
32. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev,2008,223:20-38.
33. Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol,2007,37:2779-2786.
34. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA,1998,95:6930-6935.
35. Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med,1999,190:895-902.
36. Nakae S, Iwakura Y, Suto H, et al. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol,2007,81:1258-1268.
37. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med,1998,187:787-794.
38. Hoshino K, Kashiwamura S, Kuribayashi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med,1999,190:1541-1547.
39. Townsend MJ, Fallon PG, Matthews DJ, et al. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med,2000,191:1069-1075.
40. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation,2002,106:2961-2966.
41. Smithgall MD, Comeau MR, Yoon BR, et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol,2008,20:1019-1030.
42. Chen CC, Grimbaldeston MA, Tsai M, et al. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci USA,2005,102:11408-11413.
43. Likura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest,2007,87:971-978.
44. Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol,2007,82:1481-1490.
45. Suzukawa M, Likura M, Koketsu R, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol,2008,181:5981-5989.
46. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol,2008,20:791-800.
47. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood,2009,113:1526-1534.
48. Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol,2009,86:769-778.
49. Cherry WB, Yoon J, Bartemes KR, et al. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol,2008,121:1484-1490.
50. Suzukawa M, Koketsu R, Likura M, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest,2008,88:1245-1253.
51. Miller AM, Liew FY. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. Pharmacol Ther,2011,131:179-186.
52. Aoki S, Hayakawa M, Ozaki H. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem,2010,335:75-81.
53. Ciccone MM, Cortese F, Gesualdo M, et al. A novel cardiac bio-marker:ST2:a review. Molecules,2013,18:15314-15328.
54. Carlomagno G, Messalli G, Melillo RM, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol,2013,168:1545-1547.
55. Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol,2010,185:5743-5750.
56. Oshikawa K, Yanagisawa K, Tominaga S, et al. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun,2002,299:18-24.
57. Trajkovic V, Sweet MJ, Xu D. T1/ST2--an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev,2004,15:87-95.
58. Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med,2004,30:1468-1473.
59. Martinez-Rumayor A, Camargo CA, Green SM, et al. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol,2008,130:578-584.
60. Kearley J, Buckland KF, Mathie SA, et al. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med,2009,179:772-781.
61. Prefontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma:evidence of expression by airway smooth muscle cells. J Immunol,2009,183:5094-5103.
62. Kurowska-Stolarska M, Stolarski B, Kewin P, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol,2009,183:6469-6477.
63. Oshikawa K, KUroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med,2001,164:277-281.
64. Liu X, Li M, Wu Y, et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun,2009,386:181-185.
65. Mangan NE, Dasvarma A, McKenzie AN. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol,2007,37:1302-1312.
66. Hayashi H, Kawakita A, Okazaki S, et al. IL-33 enhanced the proliferation and constitutive production of IL-13 and IL-5 by fibrocytes. Biomed Res Int,2014,2014:738625.
67. Xia J, Zhao J, Shang J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol,2015,308:L619-L627.
68. Qiu C, Li Y, Li M, et al. Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice. Immunology,2013,138:76-82.
69. Walzl G, Matthews S, Kendall S, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. Exp Med,2001,193:785-792.
70. Tang Y, Guan Y, Liu Y, et al. The role of the serum IL-33/sST2 axis and inflammatory cytokines in chronic obstructive pulmonary disease. J Interferon Cytokine Res,2014,34:162-168.
71. Martin TR, Mathison JC, Tobias PS, et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest,1992,90:2209-2219.
72. Zhao L, Yao L, Yuan L, et al. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome. Cytokine,2013,64:22-24.

Previous Article
吸入硝酸及氫氟酸導致急性呼吸窘迫綜合征一例
Next Article
青蒿琥酯在肺部疾病的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

白細胞介素33及其受體ST2在肺部疾病中的作用研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content